Vis enkel innførsel

dc.contributor.authorToft, Helge Prytz
dc.contributor.authorBramness, Jørgen Gustav
dc.contributor.authorLien, Lars
dc.contributor.authorAbebe, Dawit Shawel
dc.contributor.authorWampold, Bruce E.
dc.contributor.authorTilden, Terje
dc.contributor.authorHestad, Knut
dc.contributor.authorNeupane, Sudan Prasad
dc.date.accessioned2019-01-21T13:29:58Z
dc.date.accessioned2019-02-19T14:10:20Z
dc.date.available2019-01-21T13:29:58Z
dc.date.available2019-02-19T14:10:20Z
dc.date.issued2018-09-17
dc.identifier.citationToft HP, Bramness JG, Lien L, Abebe DSA, Wampold BE, Tilden TT, Hestad K, Neupane SP. PTSD patients show increasing cytokine levels during treatment despite reduced psychological distress.. Neuropsychiatric Disease and Treatment. 2018;14:2367-2378en
dc.identifier.issn1176-6328
dc.identifier.issn1176-6328
dc.identifier.issn1178-2021
dc.identifier.urihttps://hdl.handle.net/10642/6649
dc.description.abstractBackground: A reciprocal relationship between activated innate immune system and changes in mood and behavior has been established. There is still a paucity of knowledge on how the immune system responds during psychiatric treatment. We aimed to explore circulating cytokines and assess psychiatric symptom severity scores during 12 weeks of inpatient psychiatric treatment. Methods: The study was a longitudinal assessment of 124 patients (88 women and 36 men) in treatment at Modum Psychiatric Center, Norway. The patient sample comprised a mixed psychiatric population of whom 39 were diagnosed with posttraumatic stress disorder (PTSD). Serum blood samples for cytokine analysis and measures of mental distress using Global Severity Index were collected at admission (T0), halfway (T1), and before discharge (T2). Other factors assessed were age, gender, and the use of antidepressants and anti-inflammatory drugs. Multilevel modeling was used for longitudinal analyses to assess the repeated cytokine samples within each patient. Results: Overall level of IL-1RA was higher in PTSD patients when compared to those without PTSD (P=0.021). The level of IL-1β, MCP-1, and TNF-α increased over time in PTSD compared to non-PTSD patients (P=0.025, P=0.011 and P=0.008, respectively). All patients experienced reduced mental distress as measured by self-reported Global Severity Index scores. Stratified analysis showed that PTSD patients who used anti-inflammatory drugs had higher levels of IL-1β (P=0.007) and TNF-α (P=0.049) than PTSD patients who did not use such drugs. Conclusion: The study indicates that traumatized patients may have a distinct neuroimmune development during recovery. Their activated immune system shows even further activation during their rehabilitation despite symptom reduction.en
dc.description.sponsorshipWe also want to thank Innlandet Hospital Trust, Health Region South-East, Norway, for funding this study.en
dc.language.isoenen
dc.publisherDove Medical Pressen
dc.relation.ispartofseriesNeuropsychiatric Disease and Treatment;Volume 2018:14
dc.rights© 2018 Toft et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).en
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/
dc.subjectCytokinesen
dc.subjectTraumasen
dc.subjectInflammationsen
dc.subjectPosttraumatic stress disordersen
dc.subjectImmune activationsen
dc.titlePTSD patients show increasing cytokine levels during treatment despite reduced psychological distress.en
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2019-01-21T13:29:58Z
dc.description.versionpublishedVersionen
dc.identifier.doihttp://dx.doi.org/10.2147/NDT.S173659
dc.identifier.cristin1611058
dc.source.journalNeuropsychiatric Disease and Treatment


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

© 2018 Toft et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Med mindre annet er angitt, så er denne innførselen lisensiert som © 2018 Toft et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).